All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
Innate Pharma SA’s unexpected return to partner Astrazeneca plc all rights, in the U.S. and EU, to Lumoxiti (moxetumomab pasudotox-tdfk) for hairy cell leukemia likely triggered unease in at least some investors.